SciSparc Completes Exclusive License Agreement
SciSparc Ltd. (Nasdaq: SPRC), a specialized clinical-stage pharmaceutical company focused on addressing central nervous system disorders, has announced the successful completion of an Exclusive Patent License Agreement with Polyrizon Ltd. This agreement empowers Polyrizon to develop and sublicense SciSparc's SCI-160 program, which is primarily aimed at pain management solutions.
Overview of the Licensing Agreement
As part of this agreement, SciSparc will receive consideration valued at $3 million in Polyrizon securities. Furthermore, if specific development milestones are achieved, SciSparc could earn milestone payments totaling around $3 million in cash. These terms highlight the significant recognition of SciSparc's proprietary technology within the pain treatment sector.
Composition and Effectiveness of SCI-160
SCI-160 is an advanced synthetic blend of cannabinoids and N-acylethanolamines, specifically targeting pain relief. Previous pre-clinical studies have demonstrated that this combination effectively mediates analgesic effects in the peripheral nervous system while minimizing significant side effects, thus benefiting individuals suffering from both acute and chronic pain.
Comparison with Traditional Pain Management Solutions
Notably, SCI-160 has shown a favorable tolerance profile, with no significant adverse clinical effects reported. Research suggests that its analgesic properties could rival, and in some instances, surpass the potency of high-dose morphine. This is particularly important given the rising public health concerns associated with prescription opioid abuse.
Significance of the License Agreement
Granting global rights for the SCI-160 program to Polyrizon represents a strategic decision for SciSparc. With Polyrizon's expertise and resources in drug development, this partnership aims to accelerate the commercialization of SCI-160, ultimately enhancing the availability of effective pain management options.
About SciSparc Ltd.
SciSparc Ltd. is an innovative clinical-stage pharmaceutical company that focuses on developing cannabinoid-based therapies. Their portfolio features several promising drug development programs, including SCI-110 for treating Tourette Syndrome and Alzheimer's disease, SCI-160 for pain management, and SCI-210 for addressing autism and status epilepticus. Additionally, the company holds a controlling interest in a subsidiary that markets hemp seed oil-based products on various popular platforms.
Importance of Ongoing Research
As cannabinoids gain increased recognition for their therapeutic potential, continuous research and development are crucial. SciSparc's commitment to developing cannabinoid pharmaceuticals positions the company advantageously in the evolving landscape of pain management therapies, reflecting their dedication to enhancing patient outcomes.
Future Opportunities
With the finalization of this license agreement, SciSparc is poised to explore additional collaborations, potential revenue opportunities, and the advancement of innovative treatments in pain management. The company’s leadership team, including CEO and CFO Mr. Oz Adler, is committed to guiding SciSparc towards pioneering solutions that address unmet medical needs.
Frequently Asked Questions
What is the SCI-160 program?
SCI-160 is a proprietary pain therapy product developed by SciSparc, utilizing cannabinoids and N-acylethanolamines.
How much is the licensing deal worth?
The licensing agreement with Polyrizon is valued at up to $6 million, which includes $3 million in securities and potential milestone payments.
What conditions does SCI-160 aim to treat?
SCI-160 is designed to address various pain conditions, focusing on providing relief for both acute and chronic pain.
Who is SciSparc Ltd.?
SciSparc Ltd. (Nasdaq: SPRC) is a clinical-stage pharmaceutical company dedicated to developing cannabinoid-based therapies for mental health and central nervous system disorders.
How does SCI-160 compare to opioids?
SCI-160 has demonstrated comparable analgesic effects to high-dose morphine, without the significant risk of adverse effects that are often associated with opioids.
